Gerry Sorge

Download your copy of Tech and Talent: The Future of Life Science, our latest industry e-book. This guide explores cutting-edge technological advancements and digital innovations that are transforming the life sciences industry. It also addresses the challenges businesses are facing and the skills gaps that demand a new approach to hiring. https://lnkd.in/ewWvJejS

9

Boehringer Ingelheim and Circle Pharma, Inc. are tackling one of the most complex challenges in #CancerTreatment with a groundbreaking approach. Their recent collaboration, valued at up to $607 million in milestone payments, aims to develop a first-in-class cyclin inhibitor that targets uncontrolled cell growth—a key factor in many cancers. By utilizing Circle Pharma's innovative macrocycle platform, this partnership is poised to address difficult-to-treat tumors, offering new hope for patients and advancing the boundaries of precision medicine. Leading Circle Pharma, Inc.’s strategic vision is David J. Earp, JD, PhD, CEO, with Paul Park, Chief Business Officer, driving business development efforts. Together, they are shaping the future of cancer therapeutics with a focus on delivering transformative solutions for unmet clinical needs. #Biotech #CancerResearch #PrecisionMedicine #Innovation #Oncology #DrugDevelopment #Pharma #MacrocycleTherapies #LifeSciences

6

1 Comment

Is #MedicationPooling difficult to implement? Are supply managers seeing the benefits? Get answers to these and other questions to determine if your #ClinicalDevelopment program could benefit from pooling. https://lnkd.in/easjJYKZ #IRT #RTSM #TrialSupplyManagement #ClinicalTrials Malcolm Morrissey

2

💊 Industry News Roundup 💊 🧠 Scientists, at Epoch Biotech, have discovered a new genetic clue for delaying Alzheimer's - this has been inspiring drug discovery and could be ground-breaking. 💲 Emergent BioSolutions sold their Baltimore facility for $30M to Bora Pharmaceuticals, which included 350 of Emergent's employees 🔥 Novo Nordisk office building in Denmark, set fire again. This is the third time in the last month - everyone was safe. ➕ Zealand Pharma hits early efficacy goal for amylin weight loss candidate - another movement in the obesity space 👀 😢 Cara Therapeutics have had to cut their workforce after trial failure 😍 iOnctura raises 80M to advance early-stage eye cancer treatment 👁 ❤️ Silence Therapeutics plc siRNA candidate for cardiovascular disease is continuing to deliver in Phase 2 trials!!! 💲 The target is set for new obesity biotech UroGen Pharma, aiming to raise over $107M 🐥 A tweet about a gene led a start-up called Marea raise $190M to develop a drug to lower a type of cholesterol, a new way of maybe attacking cardiovascular disease An exciting time in the biotech space, and if you haven't already - give our podcast The BioHub Podcast a follow.

11

1 Comment

The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for #cancer to #rarediseases 🧬 Stay ahead of the latest in #biotech and learn how these #FDA decisions could shape the future of healthcare.

12

🌟 The Life Sciences Industry: Complex Hiring Needs Require Expert Solutions In a sector as innovative as life sciences, finding the right talent isn’t just about filling roles—it’s about addressing the unique challenges of specialized skills gaps, rapid scientific advancements, and strict regulatory demands. Dive into how SRG understands and meets the intricate hiring needs of this dynamic industry. 🔬💡 Read more: https://lnkd.in/gaeTzmfC

3

💡 Want to know what’s fueling growth in the life sciences industry? It all comes down to one thing: talent. Our new blog dives deep into the key factors driving hiring success and what companies can do to stand out in this competitive space. Read more here: https://lnkd.in/emdTKCPV #LifeScience #TalentAcquisition #LifeSciencesCareers #IndustryGrowth #SRGTalent

1

𝗗𝗮𝗶𝗹𝘆 𝗡𝗲𝘂𝗿𝗼-𝗯𝗶𝘁𝗲𝘀 🧠: 💵𝘾𝙤𝙣𝙜𝙧𝙖𝙩𝙪𝙡𝙖𝙩𝙞𝙤𝙣𝙨 to CereVasc who secures $70 million series B financing, following FDA approval of STRIDE study 𝗦𝗼, 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲𝘆 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘂𝘀𝗲 𝘁𝗵𝗶𝘀 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗳𝗼𝗿? 🧑‍💻Support the clinical and regulatory development of the company’s novel eShunt system ⚕️Fund their upcoming STRIDE pivotal study involving patients with normal-pressure hydrocephalus. 🤔𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗱𝗼? Their eShunt System is a minimally invasive approach to treating hydrocephalus. The System comprises an endovascularly implantable CSF shunt and associated delivery component. This is designed to avoid the need for: ⭐Invasive surgery ⭐General anesthesia ⭐Extended hospitalization ⭐Post-procedure pain management. #hydrocephalus #brainhealth #minimallyinvasive #patientoutcomes #neurovascular https://lnkd.in/e-R5wkkQ https://lnkd.in/enfjKs_E

10

🚀 Bristol Myers Squibb Q2 2024: Strong Results and Upgraded Guidance! 💊 Bristol Myers Squibb (BMS) has reported impressive second-quarter results, driven by robust sales from Eliquis and Opdivo. The company is also making significant strides in cost-cutting, aiming for $1.5 billion in savings by 2025. 📊 Key Highlights: -Q2 Revenues: $12.2 billion, an 11% YoY increase. -Eliquis: $3.5 billion in global sales, up 7%. -Opdivo: $2.4 billion in sales, up 11%. -Revlimid: $1.3 billion, despite an 8% decline. -CAR-T Therapies: Breyanzi ($153 million, 53% growth) and Abecma ($95 million). 💡 Encouraged by these results, BMS has raised its full-year 2024 guidance, now expecting earnings per share of 60 to 90 cents. 💼 As part of its strategic realignment, BMS plans to lay off 2,200 employees by the end of 2024, prioritizing investments with the greatest potential. 🔬 R&D Update: -Cendakimab: Successful Phase III trial in eosinophilic esophagitis. -Alnuctamab: Development discontinued for multiple myeloma. BMS continues to innovate and adapt, ensuring a promising future for its portfolio and stakeholders. #BMS #Pharma #Q2Results #Healthcare #Innovation #CostCutting #Eliquis #Opdivo #Revlimid #CARTTherapy #Biotech #MedicalResearch #BusinessGrowth

3

1 Comment

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/g463TbZF #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

2

From funding and staffing to AI and automation, we're exploring current and future issues in the lab industry. Gain insight and discover potential solutions when you access our new resources page for lab leaders. Read more: https://lnkd.in/gy84_ned #staffing #Equipment #Technology #data #analytics #process #qualityimprovement

1

Prefilled syringes \(PFSs\) are becoming the go-to for new injectable biologics. Transitioning from vial to PFS comes with its challenges. This article highlights the benefits and explores solutions for overcoming the pitfalls. https://ow.ly/xsQK50TJgch https://bit.ly/3NvPbnq

1

𝗧𝗵𝗲 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗖𝗗𝗠𝗢 𝗦𝘂𝗿𝗴𝗲 📈 The Biologics CDMO market is experiencing significant growth, fueled by their rising demand. Valued at $18 billion in 2024, biologics are expected to grow at a CAGR of 11.8%, reaching $55 billion by 2034 🚀 𝘽𝙪𝙩 𝙒𝙝𝙮 𝙏𝙝𝙚 𝙎𝙪𝙧𝙜𝙚? 🔴 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗗𝗲𝗺𝗮𝗻𝗱: New biologics are transforming medicine, with blockbuster drugs leading the charge. 🔴 𝗢𝘂𝘁𝘀𝗼𝘂𝗿𝗰𝗶𝗻𝗴 𝗕𝗼𝗼𝗺: Pharma companies are increasingly turning to CDMOs to handle the complexities of biologics manufacturing. 🔴 𝗧𝗲𝗰𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀: Cutting-edge technologies like single-use systems and continuous manufacturing are making production faster and cheaper. 🔴 𝗙𝗮𝘀𝘁𝗲𝗿 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀: Regulatory bodies are clearing the path for innovative therapies, making CDMOs with regulatory expertise more valuable than ever. To my 𝘽𝙞𝙤𝙡𝙤𝙜𝙞𝙘𝙨 𝘾𝘿𝙈𝙊 𝘾𝙤𝙢𝙢𝙚𝙧𝙘𝙞𝙖𝙡 𝙣𝙚𝙩𝙬𝙤𝙧𝙠, I am exclusively working on several retained projects for the following positions: ✔ 𝑽𝒊𝒄𝒆 𝑷𝒓𝒆𝒔𝒊𝒅𝒆𝒏𝒕 𝒐𝒇 𝑪𝒐𝒎𝒎𝒆𝒓𝒄𝒊𝒂𝒍 𝑫𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 (𝑵𝒐𝒓𝒕𝒉 𝑨𝒎𝒆𝒓𝒊𝒄𝒂) ✔ 𝑽𝒊𝒄𝒆 𝑷𝒓𝒆𝒔𝒊𝒅𝒆𝒏𝒕 𝒐𝒇 𝑩𝒖𝒔𝒊𝒏𝒆𝒔𝒔 𝑫𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 (𝑬𝒖𝒓𝒐𝒑𝒆) ✔ 𝑺𝒆𝒏𝒊𝒐𝒓 𝑫𝒊𝒓𝒆𝒄𝒕𝒐𝒓 𝒐𝒇 𝑪𝒐𝒎𝒎𝒆𝒓𝒄𝒊𝒂𝒍 𝑫𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 (𝑬𝒖𝒓𝒐𝒑𝒆) ✔ 𝑫𝒊𝒓𝒆𝒄𝒕𝒐𝒓 𝒐𝒇 𝑩𝒖𝒔𝒊𝒏𝒆𝒔𝒔 𝑫𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 (𝑬𝒖𝒓𝒐𝒑𝒆) Feel free to drop me a note on LinkedIn or an email ([email protected]) for a confidential discussion. #cdmo #biologics #commercial #businessdevelopment #fraserdove

29

Good news for the Pharmaceutical CDMO Market as it's expected to reach $298.8 billion by 2033 📈 🌎 North America was highlighted as dominating the market with a robust pharmaceutical industry, high outsourcing rates, and advanced CDMO capabilities, driven by a strong regulatory framework and extensive drug development activities. The report also discusses 6 factors driving this market growth: 1️⃣ Rising Complexity in Drug Development 2️⃣ Cost-Effective Outsourcing Solutions 3️⃣ Flexibility and Scalability 4️⃣ Technological Advancements 5️⃣ Strategic Partnerships 6️⃣ Globalization of Pharmaceutical Supply Chains The key players in the market will come as no surprise with Lonza, Recipharm, Catalent Pharma Solutions, Samsung Biologics and Thermo Fisher Scientific among the companies mentioned. Read more from this report in the comments below ⬇️ #CDMO #Pharmaceutical #Pharma

38

2 Comments

👉 Accelerate your process development with our upstream trial offerings. Click below to get started today! 👨‍🔬👩‍🔬📄 #CellAmplification #Collaboration #UpstreamSolutions * * 🔬Explore our Trial Possibilities for Cell Amplification: • Adapt your CHO cell to chemically-defined cell culture media and prepare the ground for an enhanced protein expression levels in combination with our innovative feeds • Adapt your HEK or insect cell to chemically defined cell culture media, including adherent to suspension adaptation for HEK293. Assess impact on cell growth. • Intensify your seed train N-1 perfusion with single-use bioreactor, cell retention solutions and cell amplification optimized media (1–2.5 L working volumes)

11

🚀 Exciting News! Kyowa Kirin International plc. Kirin is expanding its manufacturing footprint with a massive $530M investment in North Carolina! 🌟 They're thrilled to announce the construction of a cutting-edge, 171,700-square-foot biologics plant in Sanford, set to be fully operational by 2027. This state-of-the-art facility will produce innovative biologic therapies, including next-generation antibodies, for clinical trials and commercial use. This marks Kyowa Kirin's first manufacturing site in North America, complementing our existing plant in Takasaki, Japan, and ensuring a smooth tech transfer process. This strategic expansion is supported by state and local incentives of up to $10 million over 12 years, creating over 100 high-paying jobs! 💼💡 The decision to set up in North Carolina is a testament to the state's vibrant biopharma hub and its deep talent pool, which they plan to leverage. #KyowaKirin #Biopharma #NorthCarolina #Innovation #JobCreation #Biologics #Pharmaceuticals #LifeSciences #ResearchTrianglePark #DrugDevelopment #TechTransfer #NextGenTherapies #ClinicalTrials #CommercialUse

1

1 Comment